2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Myeloid STAT3 promotes lung tumorigenesis by transforming tumor immunosurveillance into tumor-promoting inflammation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          One of the most fundamental and challenging questions in the cancer field is how immunity in cancer patients is transformed from tumor immunosurveillance to tumor-promoting inflammation. Here, we identify the transcription factor STAT3 as the culprit responsible for this pathogenic event in lung cancer development. We found that antitumor type 1 CD4 + T helper (Th1) cells and CD8 + T cells were directly counter-balanced in lung cancer development with tumor-promoting myeloid-derived suppressor cells (MDSCs) and suppressive macrophages, and that activation of STAT3 in MDSCs and macrophages promoted tumorigenesis through pulmonary recruitment and increased resistance of suppressive cells to CD8 + T cells, enhancement of cytotoxicity towards CD4 + and CD8 + T cells, induction of regulatory T cell (Treg), inhibition of dendritic cells (DCs), and polarization of macrophages toward the M2 phenotype. The deletion of myeloid STAT3 boosted antitumor immunity and suppressed lung tumorigenesis. These findings increase our understanding of immune programming in lung tumorigenesis and provide a mechanistic basis for developing STAT3-based immunotherapy against this and other solid tumors.

          Related collections

          Author and article information

          Journal
          101614637
          41946
          Cancer Immunol Res
          Cancer Immunol Res
          Cancer immunology research
          2326-6066
          2326-6074
          9 February 2017
          20 January 2017
          March 2017
          01 March 2018
          : 5
          : 3
          : 257-268
          Affiliations
          [1 ]University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
          [2 ]Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
          [3 ]Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
          [4 ]Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
          Author notes
          [* ]Correspondence: Zhaoxia Qu, Hillman Cancer Center, Suite 1.19e, 5117 Centre Avenue, Pittsburgh, PA 15213, USA. Phone: 412-623-1111; Fax: 412-623-1415; quz@ 123456upmc.edu ; or Gutian Xiao, Hillman Cancer Center, Suite 1.19a, 5117 Centre Avenue, Pittsburgh, PA 15213, USA. Phone: 412-623-5410; Fax: 412-623-1415; xiaog2@ 123456upmc.edu
          [5]

          Current address: Department of Pharmacology, University of Minnesota, Minneapolis, MN55455, USA.

          Article
          PMC5334370 PMC5334370 5334370 nihpa846191
          10.1158/2326-6066.CIR-16-0073
          5334370
          28108629
          0f7d7d17-ca02-4d82-bea9-f2b69c380ee1
          History
          Categories
          Article

          MDSC,STAT3,lung cancer,myeloid cell
          MDSC, STAT3, lung cancer, myeloid cell

          Comments

          Comment on this article